| Description | Cefoxitin (Rephoxitin) is a broad-spectrum, orally available second-generation cephalosporins antibiotic. Cefoxitin interferes with the synthesis of bacterial cell walls. Its activity profile includes Gram-negative and Gram-positive bacteria, and is commonly used in abdominal cavity infections, pelvic infections, and certain types of gynecological infections, and is highly effective against anaerobic bacteria. |
| In vitro | Cefoxitin has good activity against Gram-positive bacteria. The MICs for several Gram-positive pathogens are in the range of 1-6 μg/mL[1].Cefoxitin (1.25 µM/mL) exhibits high efficacy killing B. burgdorferi at concentration [2]. |
| In vivo | 给予C3H/HeN小鼠模型每天通过腹腔注射方式连续5天使用20 mg/kg剂量的Cefoxitin，有效根除了B. burgdorferi。[2] |
| Target activity | PBP2b:0.19 μg/mL, PBP5:0.19 μg/mL, PBP4:0.14 μg/mL, PBP3:1.04 μg/mL, PBP2a:0.72 μg/mL |
| Synonyms | Rephoxitin, Cefoxitinum |
| molecular weight | 427.45 |
| Molecular formula | C16H17N3O7S2 |
| CAS | 35607-66-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 90.0 mg/mL (210.6 mM), Sonication is recommended. |
| References | 1. Stapley EO, et al. Cefoxitin and cephamycins: microbiological studies. Rev Infect Dis. 1979;1(1):73-89. 2. Pothineni VR, et al. In vitro and in vivo evaluation of cephalosporins for the treatment of Lyme disease. Drug Des Devel Ther. 2018;12:2915-2921. 3. Miller AK, et al. Cefoxitin, a semisynthetic cephamycin antibiotic: in vivo evaluation. Antimicrob Agents Chemother. 1974;5(1):33-37. 4. Sharifzadeh S, et al. Harnessing β-Lactam Antibiotics for Illumination of the Activity of Penicillin-Binding Proteins in Bacillus subtilis. ACS Chem Biol. 2020;15(5):1242-1251. |